Department of Radiology, Dresden University Hospital, Fetscherstr. 74, 01307 Dresden, Germany.
MAGMA. 2013 Feb;26(1):49-55. doi: 10.1007/s10334-012-0342-7. Epub 2012 Sep 16.
To evaluate the feasibility of positron emission tomography/magnetic resonance imaging (PET/MR) with (18)fluoro-2-deoxyglucose (FDG) for therapy response evaluation of malignant lymphoma.
Nine patients with malignant lymphoma who underwent FDG-PET/MR before and after chemotherapy were included in this retrospective study. Average time between the two scans was 70 days. The scans were evaluated independently by two nuclear medicine physicians. The Ann Arbor classification was used to describe lymphoma stage. Furthermore, the readers also rated PET image quality using a five point scale. Weighted kappa (κ) was used to calculate interrater agreement.
The initial scan showed foci of increased FDG uptake in all patients, with Ann Arbor stage varying between I and IV. In the follow-up examination, all but one patient showed complete response to chemotherapy. PET image quality was rated as very good or excellent for all scans. Interrater agreement was excellent regarding Ann Arbor stage (κ = 0.97) and good regarding image quality (κ = 0.41).
PET/MR shows promising initial results for therapy response evaluation in lymphoma patients.
评估正电子发射断层扫描/磁共振成像（PET/MR）联合（18）氟-2-脱氧葡萄糖（FDG）在恶性淋巴瘤治疗反应评估中的可行性。
本回顾性研究纳入了 9 例在化疗前后接受 FDG-PET/MR 的恶性淋巴瘤患者。两次扫描之间的平均时间为 70 天。两名核医学医师对扫描结果进行独立评估。采用 Ann Arbor 分类描述淋巴瘤分期。此外，读者还使用五分制对 PET 图像质量进行评分。采用加权 κ（κ）计算组内一致性。
初始扫描显示所有患者均有 FDG 摄取增加的病灶，Ann Arbor 分期在 I 期至 IV 期之间。在随访检查中，除 1 例患者外，所有患者对化疗均有完全缓解。所有扫描的 PET 图像质量均被评为非常好或极好。在 Ann Arbor 分期方面，组内一致性极好（κ=0.97），在图像质量方面，组内一致性良好（κ=0.41）。
PET/MR 在淋巴瘤患者的治疗反应评估中显示出有前途的初步结果。
